Noopur Raje, MD, on Current CAR T Options in Multiple Myeloma

Video

The director of the Center for Multiple Myeloma at Mass Gen discussed current CAR T-cell therapies in multiple myeloma.

This content originally appeared on our sister site, OncLive.

Chimeric antigen receptor (CAR) T-cell therapies are a growing option for the treatment of multiple myeloma. Idecabtagene vicleucel (ide-cel; Abecma) was approeved in March 2021 for the treatment of patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy. Ciltacabtagene autoleucel (cilta-cel; Carvykti) was apprpved in February 2022 for the treatment of adult patients with relapsed/refractory multiple myeloma following 4 or more prior lines of therapy.

Patients eligible for CAR T-cell therapy treatment have highly refractory disease and have been exposed to a majority of treatment options, including lenalidomide (Revlimid), pomalidomide (Pomalyst), bortezomib (Velcade), carfilzomib (Kyprolis), and an anti-CD38 monoclonal antibody.

OncLive spoke with Noopur Raje, MD, to learn more about the current CAR T-cell therapy options available for patients with relapsed/refractory multiple myeloma.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.